SOUTH
SAN FRANCISCO, USA and
VANCOUVER, CANADA,
March 7,
2024 /PRNewswire/ - ESSA Pharma Inc.
("ESSA" or the "Company") (NASDAQ: EPIX), a clinical
stage pharmaceutical company focused on developing novel therapies
for the treatment of prostate cancer, is pleased to announce the
results of the votes on matters considered at its Annual General
Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting").
At the Meeting, the shareholders of the Company (the
"Shareholders") resolved to set the number of directors of
the Company at ten and re-elected to the board of directors, by
ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M.
Berger, Scott Requadt,
Marella Thorell, Alex Martin, Sandy
Zweifach, Philip Kantoff and
Lauren Merendino to serve in office
until the next annual meeting or until their successors are duly
elected or appointed. Detailed results of the voting in respect of
the election of directors are as follows:
|
Nominee
|
Votes
For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
|
David R.
Parkinson
|
29,947,985
|
99.73 %
|
81,989
|
0.27 %
|
|
Richard
MGlickman
|
29,948,035
|
99.73 %
|
81,939
|
0.27 %
|
|
Gary Sollis
|
29,945,788
|
99.72 %
|
84,186
|
0.28 %
|
|
Franklin M.
Berger
|
29,937,249
|
99.69 %
|
92,725
|
0.31 %
|
|
Scott
Requadt
|
29,947,985
|
99.73 %
|
81,989
|
0.27 %
|
|
MarellaThorell
|
23,840,414
|
79.39 %
|
6,189,560
|
20.61 %
|
|
Alex Martin
|
30,014,431
|
99.95 %
|
15,543
|
0.05 %
|
|
Sandy
Zweifach
|
30,013,358
|
99.94 %
|
16,616
|
0.06 %
|
|
Philip
Kantoff
|
30,014,381
|
99.95 %
|
15,593
|
0.05 %
|
|
Lauren
Merendino
|
30,015,635
|
99.95 %
|
14,339
|
0.05 %
|
At the Meeting, the Shareholders also approved: (i) the
re-appointment of Davidson & Company LLP, Chartered
Professional Accountants, as auditors of the Company; (ii) an
amendment to the Company's omnibus incentive plan (as amended, the
"Amended Omnibus Plan") to increase the number of common
shares of the Company reserved and available for issuance under the
Amended Omnibus Plan; and (iii) on a non-binding advisory basis,
the compensation of the Company's named executive officers.
Contact Information:
David Wood
Chief
Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: dwood@essapharma.com
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302083628.html
SOURCE ESSA Pharma Inc